Syndax Pharmaceuticals Inc (SNDX)
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (85%) **Content type:** Clinical